Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2025-05-22 00:00:00 ET · period of report 2025-05-20 · accession 0001415889-25-014185 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-22 | 2025-05-20 | SPRY | SAUNDERS BRENT L | Dir | M - OptEx | $1.01 | +120.0K | 120.0K | New | +$121.2K |
| D | 2025-05-22 | 2025-05-20 | SPRY | SAUNDERS BRENT L | Dir | S - Sale+OE | $14.25 | -120.0K | 0 | -100% | -$1.71M |
| D | 2025-05-22 | 2025-05-20 | SPRY | SAUNDERS BRENT L | Dir | M - OptEx | $0.00 | -120.0K | 470.9K | -20% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-20 | M | A | 120,000 | $1.01 | 120,000 | D | — | — | |
| 2 | Common | Common Stock | 2025-05-20 | S | D | 120,000 | $14.25 | 0 | D | — | — | (F1) The weighted average sale price for the transaction reported was $14.2502 and the range of prices were between $14.25 and $14.26. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-05-20 | M | D | 120,000 | $0.00 | 470,950 | D | $1.01 · — to 2031-06-15 | 120,000 Common Stock | (F2) Immediately exercisable. |